SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending following its earnings release, with community members closely watching for sustained gains. Discussions revolve around AWS growth, overall profitability, and whether the stock can maintain its upward momentum or if profit-taking will lead to a reversal, similar to other tech stocks.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's earnings are driving significant discussion, with debates focusing on whether the results justify the company's high valuation and PE ratio. Community members are closely watching guidance for the next quarter, particularly regarding iPhone sales and growth in China. Some traders express concerns about overvaluation and are considering short positions, while others remain bullish, anticipating a continued climb towards higher price targets.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's stock is trending following a strong earnings report, with revenue and EPS exceeding analyst expectations and user growth remaining solid. The community is buzzing about the potential for a continued rally towards previous highs, although some traders are wary of a possible pullback. Discussions also include the impact of AI and data licensing deals on Reddit's revenue streams, as well as a debate on the stock's valuation relative to its growth.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending amid mixed reactions to its earnings report, which featured strong revenue growth but missed EPS estimates. The community is debating whether the company's heavy Bitcoin holdings and unrealized gains justify the current stock price, with some anticipating a short squeeze while others point to manipulation and dilution concerns. Analysts remain bullish with high price targets despite recent volatility.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

RKT is trending as investors discuss the potential impact of AI integration and the recent earnings report. Community members are focused on Q4 expenses, the Redfin/Mr. Cooper merger, and future earnings potential amid fluctuating interest rates. Bullish sentiment is building around the company's long-term growth prospects in the mortgage industry.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to community discussion around earnings and a recent offering, with debates focusing on the significance of new deals and the company's growth potential. Bulls emphasize the disruptive nature of GSIT's technology and potential partnerships, while bears express concerns about disappointing results and valuation. Some investors speculate about a possible buyout or strategic investment from larger players in the semiconductor industry.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest recent earnings and pipeline developments, with discussions focused on revenue guidance and the potential of their next-generation inhibitor. Community sentiment appears mixed, with some expressing confidence in management's vision and others concerned about market undervaluation and the ongoing CMS legal battle. Bullish investors are hoping for a breakout driven by strong execution and potential M&A activity.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

DXCM is trending amid mixed sentiment following earnings and news of a leadership transition. While some investors see a buying opportunity due to growth in key markets and a raised full-year revenue outlook, others are concerned about margin pressures, competition, and product quality, particularly with the G7 sensor; the community is actively debating the stock's near-term trajectory.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending as investors react to an analyst upgrade from JP Morgan citing potential in Base monetization and USDC yield opportunities. Community chatter suggests a possible run to $400, while others express skepticism based on past earnings performance, and anticipate volatility ahead of the Q3 report. The stock's recent decoupling from Bitcoin's price action is also being noted.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

LUMN is trending due to positive sentiment surrounding its AI connectivity fabric and recent partnerships, particularly with Palantir, fueling speculation about future government contracts. Community members are actively discussing the potential for a significant earnings beat and a re-rating as a tech company, while also weighing the company's debt against its growth prospects in the AI infrastructure space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Equity

Nasdaq-listed shares of Autolus Therapeutics PLC (AUTL) were in the spotlight on Friday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-positive-chmp-opinion">announced</a> that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve its Obe-cel therapy for the treatment of a particular type of blood cancer.Obe-cel is short for Obecabtagene Autoleucel. The CHMP has recommended that the European Commission approve it for the treatment of adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia, an aggressive type of blood cancer that can also involve the lymph nodes, spleen, liver, central nervous system, and other organs.According to Autolus, there are about 6,000 new cases of acute Lymphoblastic Leukemia diagnosed every year in Europe.The committee’s recommendation was based on the results of the company’s open-label, multiple-centre study and will serve as the basis for the commission’s final decision on Autolus’ marketing authorization application.The European Commission's decision will apply to all 27 European Union Member States, Iceland, Norway, and Liechtenstein.Obe-cel received approval from the U.S. Food and Drug Administration in November 2024 and conditional marketing authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency in April.On Stocktwits, retail sentiment around AUTL improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘neutral’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_12_01_00_PM_png_a607fcc3b0.webp" alt="AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the therapy receiving approval in the EU.<stembedurl>https://stocktwits.com/Mancunian/message/615691105</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by about 42% this year and 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-backed-anthropic-claude-blackmails-engineer/ch0QVgWRbqH">Amazon-Backed Anthropic's AI Model Reportedly Blackmails Engineer Having An Affair To Avoid Being Shut Down In Test Run</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens

CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 

Shares of biotech Galapagos NV (GLPG) dipped nearly 1% in pre-market trade on Tuesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.glpg.com/press-releases/galapagos-announces-departure-of-thad-huston-cfo-and-coo-as-of-august-1-2025/">announced</a> the departure of its CFO and COO, Thad Huston, effective August 1, 2025.The company said Huston has decided to leave and return to the U.S. for personal and professional reasons. It added that it expects to announce a new CFO “in the coming months,” but did not share a definitive timeline.Huston joined Galapagos in July 2023 from Kite Pharma, Inc. Before that, he worked for over 25 years at Johnson &amp; Johnson.CEO Paul Stoffels said that Huston will stay in his role until Aug. 1 to “ensure a smooth handover of responsibilities.”Galapagos, which has operations in Europe and the U.S., reported its full-year 2024 financial results earlier this year. The company logged a 15% jump in total net revenue to €275.6 million (about $312 million), while diluted earnings per share fell to $1.12 from $3.21 year-over-year (YoY).As of the end of 2024, it had €3.3 billion in cash and financial investments and said that it intends to separate into two publicly traded companies and establish SpinCo with approximately €2.45 billion in current cash.A shareholder meeting regarding the separation of Galapagos into two publicly traded entities is expected to be convened in mid-2025.On Stocktwits, retail sentiment about Galapagos fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:650/148;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_8_24_57_AM_png_80bd7d6071.webp" alt="GLPG's Sentiment Meter and Message Volume as of 8:25 a.m. ET on April 14, 2025 | Source: Stocktwits" width="650" height="148"><figcaption>GLPG's Sentiment Meter and Message Volume as of 8:25 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> is down by over 13% year-to-date and by nearly 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnsons-q1-earnings-beat-estimates/chQRaxWRbaH">Johnson &amp; Johnson’s Q1 Earnings Beat Estimates, 2025 Guidance Revised To Account For Intra-Cellular Therapies Acquisition: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com(Exchange Rate: 1 Euro = 1.13 USD)

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed

The company expects to announce a new CFO “in the coming months.”

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

ALPS ETF Trust - ALPS Medical Breakthroughs ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

SBIO
ALPS Fund Services - ALPS Medical Breakthroughs ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SBIO News

SBIOALPS Fund Services - ALPS Medical Breakthroughs ETF